Seo Jun-Won, Kim Da-Young, Yun Nara, Kim Dong-Min
Division of Infectious Disease, Department of Internal Medicine, College of Medicine, Chosun University, Gwangju 61453, Korea.
Microorganisms. 2022 Aug 2;10(8):1556. doi: 10.3390/microorganisms10081556.
Coronavirus disease 2019 (COVID-19)-associated coagulopathy is an acute illness characterized by thrombosis with or without hemorrhage after COVID-19 infection. Clinical symptoms of COVID-19-associated coagulopathy can occur at any anatomical site. Various forms of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, are common in acutely ill patients with COVID-19. Laboratory findings, such as D-dimer and platelet counts, can help diagnose COVID-19-associated coagulopathy. Anticoagulation using direct oral anticoagulants and low-molecular-weight heparin is essential for the treatment of COVID-19-associated coagulopathy. Prophylactic anticoagulants are important in preventing COVID-19-associated coagulopathy in patients with severe COVID-19. In particular, the early initiation of prophylactic anticoagulation in patients with COVID-19 can improve survival rates without the risk of serious bleeding events.
2019冠状病毒病（COVID-19）相关凝血病是一种急性疾病，其特征是在COVID-19感染后出现伴有或不伴有出血的血栓形成。COVID-19相关凝血病的临床症状可出现在任何解剖部位。各种形式的静脉血栓栓塞，包括深静脉血栓形成和肺栓塞，在患有COVID-19的急性病患者中很常见。实验室检查结果，如D-二聚体和血小板计数，有助于诊断COVID-19相关凝血病。使用直接口服抗凝剂和低分子量肝素进行抗凝对于治疗COVID-19相关凝血病至关重要。预防性抗凝剂对于预防重症COVID-19患者发生COVID-19相关凝血病很重要。特别是，在COVID-19患者中早期开始预防性抗凝可以提高生存率，而不会有严重出血事件的风险。
